Blue Owl Capital Holdings LP Acquires Shares of 2,934,015 Context Therapeutics Inc. $CNTX

Blue Owl Capital Holdings LP purchased a new position in Context Therapeutics Inc. (NASDAQ:CNTX) in the second quarter, Holdings Channel reports. The fund purchased 2,934,015 shares of the company’s stock, valued at approximately $1,625,000.

A number of other hedge funds have also recently added to or reduced their stakes in CNTX. BlackRock Inc. acquired a new position in shares of Context Therapeutics in the 2nd quarter valued at about $3,417,000. Octagon Capital Advisors LP bought a new stake in Context Therapeutics in the first quarter valued at $13,755,000. Millennium Management LLC bought a new stake in Context Therapeutics in the fourth quarter valued at $3,824,000. Marshall Wace LLP boosted its holdings in shares of Context Therapeutics by 7,153.7% during the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after acquiring an additional 2,557,448 shares during the period. Finally, Timothy G. Youngquist 2020 Irrevocable Trust acquired a new position in shares of Context Therapeutics during the second quarter valued at $110,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on CNTX. Citigroup restated an “outperform” rating on shares of Context Therapeutics in a research note on Thursday, August 6th. Lifesci Capital cut Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Weiss Ratings downgraded Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 6th. Maxim Group decreased their price target on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. Finally, Wall Street Zen lowered Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $6.17.

Context Therapeutics Trading Up 6.6%

Shares of Context Therapeutics stock opened at $0.52 on Friday. The company’s 50-day moving average price is $0.61 and its two-hundred day moving average price is $1.82. Context Therapeutics Inc. has a 52 week low of $0.43 and a 52 week high of $3.62. The stock has a market cap of $47.75 million, a PE ratio of -1.08 and a beta of 1.74.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.06). On average, equities analysts predict that Context Therapeutics Inc. will post -0.4 EPS for the current fiscal year.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.